

Piotr Eder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2062923/publications.pdf>

Version: 2024-02-01

90
papers

2,147
citations

516215

16
h-index

276539

41
g-index

94
all docs

94
docs citations

94
times ranked

2254
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. <i>Molecules</i> , 2020, 25, 3731.	1.7	640
2	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
3	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	0.6	120
4	Nanotoxicology and Nanosafety: Safety-by-Design and Testing at a Glance. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4657.	1.2	114
5	Diet and Nutritional Factors in Male (In)fertility—Underestimated Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 1400.	1.0	79
6	Properties, Extraction Methods, and Delivery Systems for Curcumin as a Natural Source of Beneficial Health Effects. <i>Medicina (Lithuania)</i> , 2020, 56, 336.	0.8	55
7	The Role of Adipose Tissue in the Pathogenesis and Therapeutic Outcomes of Inflammatory Bowel Disease. <i>Cells</i> , 2019, 8, 628.	1.8	51
8	Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study. <i>Scientific Reports</i> , 2021, 11, 2166.	1.6	47
9	Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. <i>Archives of Medical Science</i> , 2015, 2, 353-361.	0.4	42
10	Osteoporosis in Gastrointestinal Diseases. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 185-190.	0.6	26
11	Is the Retinol-Binding Protein 4 a Possible Risk Factor for Cardiovascular Diseases in Obesity?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5229.	1.8	25
12	Iron Deficiency Anemia in Inflammatory Bowel Diseases—A Narrative Review. <i>Nutrients</i> , 2021, 13, 4008.	1.7	25
13	The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity. <i>Abdominal Imaging</i> , 2015, 40, 2210-2218.	2.0	23
14	The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease — An immunohistochemical study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 706-716.	0.6	21
15	Bone Metabolism and the c.-223C>T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease. <i>Calcified Tissue International</i> , 2016, 99, 616-624.	1.5	20
16	Biosimilar medicines — their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. <i>Przegląd Gastroenterologiczny</i> , 2014, 1, 1-3.	0.3	17
17	Prevalence of osteoporosis and osteopenia in a population of patients with inflammatory bowel diseases from the Wielkopolska Region. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 447-454.	0.3	17
18	The importance of vitamin D in the pathology of bone metabolism in inflammatory bowel diseases. <i>Archives of Medical Science</i> , 2015, 11, 1028-32.	0.4	17

#	ARTICLE	IF	CITATIONS
19	Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies. <i>Scientific Reports</i> , 2015, 5, 10223.	1.6	16
20	ESR1 Gene Variants Are Predictive of Osteoporosis in Female Patients with Crohn's Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 1306.	1.0	15
21	Cancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications. <i>Cancers</i> , 2021, 13, 1896.	1.7	15
22	Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents. <i>Przeład Gastroenterologiczny</i> , 2016, 3, 187-193.	0.3	14
23	Associations of Lifestyle Factors with Osteopenia and Osteoporosis in Polish Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2021, 13, 1863.	1.7	14
24	What Links an Increased Cardiovascular Risk and Inflammatory Bowel Disease? A Narrative Review. <i>Nutrients</i> , 2021, 13, 2661.	1.7	14
25	Hydrogels for Modified-release Drug Delivery Systems. <i>Current Pharmaceutical Design</i> , 2022, 28, 609-618.	0.9	14
26	Evaluation of antimicrobial resistance of <i>Helicobacter pylori</i> in the last 15 years in West Poland. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2015, 62, 287-293.	0.4	13
27	Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 449-453.	0.6	13
28	Current management of anal fistulas in Crohn's disease. <i>Przeład Gastroenterologiczny</i> , 2015, 2, 83-88.	0.3	12
29	Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. <i>Life</i> , 2021, 11, 943.	1.1	12
30	The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing. <i>Folia Histochemica Et Cytobiologica</i> , 2016, 54, 75-80.	0.6	12
31	Multidimensional Disadvantages of a Gluten-Free Diet in Celiac Disease: A Narrative Review. <i>Nutrients</i> , 2021, 13, 643.	1.7	11
32	Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease. <i>Frontiers in Immunology</i> , 2021, 12, 615539.	2.2	11
33	Angiogenesis-Related Proteins - Their Role in the Pathogenesis and Treatment of Inflammatory Bowel Disease. <i>Current Protein and Peptide Science</i> , 2015, 16, 249-258.	0.7	11
34	Guidelines for the management of Crohn's disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. <i>Przeład Gastroenterologiczny</i> , 2012, 6, 317-338.	0.3	10
35	The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity. <i>European Journal of Internal Medicine</i> , 2015, 26, 623-627.	1.0	10
36	The c.29T>C polymorphism of the transforming growth factor beta-1 (TGFB1) gene, bone mineral density and the occurrence of low-energy fractures in patients with inflammatory bowel disease. <i>Molecular Biology Reports</i> , 2017, 44, 455-461.	1.0	10

#	ARTICLE	IF	CITATIONS
37	Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5223.	1.8	10
38	Simple Enterographic Activity Score for Crohn's Disease: comparison with endoscopic, biochemical, and clinical findings. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 378-385.	0.3	10
39	How could nanobiotechnology improve treatment outcomes of anti-TNF therapy in inflammatory bowel disease? Current knowledge, future directions. <i>Journal of Nanobiotechnology</i> , 2021, 19, 346.	4.2	10
40	Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 257-296.	0.3	10
41	Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease. <i>Life</i> , 2021, 11, 1409.	1.1	10
42	Disturbances in apoptosis of lamina propria lymphocytes in Crohn's disease. <i>Archives of Medical Science</i> , 2015, 6, 1279-1285.	0.4	9
43	Dietary Support in Elderly Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2019, 11, 1421.	1.7	9
44	Calcium and phosphate metabolism in patients with inflammatory bowel diseases. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 588-590.	0.3	9
45	Update on the mechanisms of action of anti-TNF antibodies and their clinical implications in inflammatory bowel disease. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 772-780.	0.3	9
46	Association of serum VEGF with clinical response to anti-TNF therapy for Crohn's disease. <i>Cytokine</i> , 2015, 76, 288-293.	1.4	8
47	An increase in serum tumour necrosis factor during anti-tumour necrosis factor therapy for Crohn's disease – A paradox or a predictive index?. <i>Digestive and Liver Disease</i> , 2016, 48, 1168-1171.	0.4	8
48	Milk and dairy product consumption in patients with inflammatory bowel disease: Helpful or harmful to bone mineral density?. <i>Nutrition</i> , 2020, 79-80, 110830.	1.1	8
49	A Vicious Cycle of Osteosarcopenia in Inflammatory Bowel Diseases – Aetiology, Clinical Implications and Therapeutic Perspectives. <i>Nutrients</i> , 2021, 13, 293.	1.7	8
50	Addressing multiple gastroenterological aspects of COVID-19. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 420-430.	0.3	8
51	Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF antibodies. <i>World Journal of Gastroenterology</i> , 2017, 23, 135.	1.4	8
52	Obesity and the Brain. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6145.	1.8	8
53	Artificial Gastrointestinal Models for Nutraceuticals Research – Achievements and Challenges: A Practical Review. <i>Nutrients</i> , 2022, 14, 2560.	1.7	8
54	Osteoprotegerin, s-RANKL, and selected interleukins in the pathology of bone metabolism in patients with Crohn's disease. <i>Przegląd Gastroenterologiczny</i> , 2016, 1, 30-34.	0.3	7

#	ARTICLE	IF	CITATIONS
55	Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn's Disease Patients?. <i>Frontiers in Pharmacology</i> , 2020, 11, 1207.	1.6	7
56	Position statement of the Polish Society of Gastroenterology and the National Gastroenterology Consultant on vaccination against COVID-19 among patients with inflammatory bowel diseases. <i>Przegląd Gastroenterologiczny</i> , 2021, 16, 2-4.	0.3	7
57	Myostatin and Follistatin "New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. <i>Biomedicines</i> , 2021, 9, 1301.	1.4	7
58	Position of the expert group on the current practice and prospects for the treatment of complex perirectal fistulas in the course of Crohn's disease. <i>Polski Przegląd Chirurgiczny</i> , 2019, 91, 1-9.	0.2	7
59	Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). <i>Polish Archives of Internal Medicine</i> , 2021, 131, 226-232.	0.3	6
60	Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 91-97.	0.6	6
61	Vitamin D receptor (VDR) TaqI polymorphism, vitamin D and bone mineral density in patients with inflammatory bowel diseases. <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 955-960.	0.6	6
62	Immunogenetic, Molecular and Microbiotic Determinants of Eosinophilic Esophagitis and Clinical Practice "A New Perspective of an Old Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10830.	1.8	6
63	Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn's disease. , 2008, 118, 622-6.		6
64	Alterations in programmed cell death mechanism and their role in the pathogenesis of inflammatory bowel diseases. <i>Przegląd Gastroenterologiczny</i> , 2014, 5, 275-279.	0.3	5
65	New pharmaceuticals in inflammatory bowel disease. <i>Przegląd Gastroenterologiczny</i> , 2015, 2, 57-60.	0.3	5
66	The position statement of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 85-88.	0.3	5
67	Vitamin D, Vitamin D Receptor (VDR) Gene Polymorphisms (Apal and FokI), and Bone Mineral Density in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Densitometry</i> , 2021, 24, 233-242.	0.5	5
68	Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110364.	1.4	5
69	Agomelatine-induced liver injury in a patient with choledocholithiasis. <i>Acta Neuropsychiatrica</i> , 2015, 27, 56-59.	1.0	4
70	Treatment of Crohn's anal fistulas guided by magnetic resonance imaging. <i>Przegląd Gastroenterologiczny</i> , 2019, 14, 55-61.	0.3	4
71	The introduction of the IBD Disk in Poland " a new tool for assessing disability in patients with inflammatory bowel disease. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 55-59.	0.3	4
72	Is there a relation between vitamin D, interleukin-17, and bone mineral density in patients with inflammatory bowel disease?. <i>Archives of Medical Science</i> , 2021, 17, 662-674.	0.4	4

#	ARTICLE	IF	CITATIONS
73	Calcium and phosphate metabolism in patients with inflammatory bowel diseases. , 2015, 125, 588-90.		4
74	Social Distancing during COVID-19 Pandemic among Inflammatory Bowel Disease Patients. Journal of Clinical Medicine, 2021, 10, 3689.	1.0	3
75	Possible under-treatment of women in Poland with Crohn's disease: a subgroup analysis from a prospective multicenter study of the use of anti-TNFs. Polish Archives of Internal Medicine, 2017, 127, 674-680.	0.3	3
76	Blockers of tumour necrosis factor- α : mechanisms of action. Przegląd Gastroenterologiczny, 2011, 5, 290-298.	0.3	2
77	Guidelines for the management of ulcerative colitis. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. Przegląd Gastroenterologiczny, 2013, 1, 1-20.	0.3	2
78	Diagnostic importance of faecal markers in long-term monitoring of anti-TNF- α therapy in primary responders with Crohn's disease. Przegląd Gastroenterologiczny, 2016, 4, 232-238.	0.3	2
79	Hereditary Angioedema: An Overlooked Cause of Recurrent Abdominal Pain and Free Peritoneal Fluid. Clinical Gastroenterology and Hepatology, 2018, 16, e43-e44.	2.4	2
80	Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohn's disease. Folia Histochemica Et Cytobiologica, 2013, 51, 239-243.	0.6	2
81	Palliative treatment of anal fistulas in Crohn's disease. ANZ Journal of Surgery, 2016, 86, 148-151.	0.3	1
82	Biosimilar biological drugs in the treatment of inflammatory bowel diseases. Przegląd Gastroenterologiczny, 2019, 14, 223-227.	0.3	1
83	Does Only Sex Matter? Complexity of the Association Between Vdr Gene Bsm1 Single Nucleotide Polymorphism and Immune Response in IBD. Inflammatory Bowel Diseases, 2019, 25, e56-e57.	0.9	1
84	Two- and Three-Dimensional Spectrofluorimetric Qualitative Analysis of Selected Vegetable Oils for Biomedical Applications. Molecules, 2020, 25, 5608.	1.7	1
85	Long-term prognostic utility of selected acute phase proteins in colorectal cancer. Polish Archives of Internal Medicine, 2019, 129, 292-294.	0.3	1
86	Metabolic link between obesity and autoimmune diseases. European Cytokine Network, 2021, 32, 64-72.	1.1	1
87	Abdominal bloating "an important symptom in everyday medical practice. Przegląd Gastroenterologiczny, 2012, 4, 197-202.	0.3	0
88	Historical Upheavals and Eponyms in Crohn's Disease"Is There Any Relation?. Journal of Crohn's and Colitis, 2020, 14, 719-719.	0.6	0
89	Black esophagus: an unusual etiology of the upper gastrointestinal bleeding. Polish Archives of Internal Medicine, 2021, 131, 377-378.	0.3	0
90	Self-Medication with Drotaverine among Patients with Common Abdominal Symptoms and Treatment Efficacy from the Perspectives of Patients and General Practitioners"An Observational, Retrospective, Cross-Sectional Study Using Real-World Data. Journal of Clinical Medicine, 2022, 11, 3156.	1.0	0